Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 9/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 5/20 | 1.00 |
| ▸ | TUBB | P07437 | 5/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 5/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 5/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 5/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 5/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 5/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.78 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.72 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.70 |
| ▸ | BACE1 | P56817 | 1/20 | 0.70 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30504103 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2329679 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13674866 | 0.92 | TUBB1 (0.85) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1425136 | 0.90 | TUBB1 (0.81) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1425140 | 0.90 | TUBB1 (0.81) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL31059019 | 0.89 | TUBB1 (0.80) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL31059014 | 0.89 | TUBB1 (0.80) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL31059031 | 0.89 | TUBB1 (0.80) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL30777911 | 0.89 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL12709765 | 0.89 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8188546-A | — | — | None | — | — | JP | disclosed |
| US-9155724-B2 | Combination methods for treatment of disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2670739-B1 | BENZOTHIAZOLE HYBRIDS USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2015-04-01 | — | — | EP | disclosed |
| CN-104292140-A | Farnesyl thiosalicylic acid analogue containing chalcone framework, preparation method and purpose thereof | UNIV NANTONG | 2015-01-21 | — | — | CN | disclosed |
| US-8921552-B2 | Benzothiazole hybrids useful as anticancer agents and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-12-30 | — | — | US | disclosed |
| US-20140039190-A1 | BENZOTHIAZOLE HYBRIDS USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-02-06 | — | — | US | disclosed |
| EP-2670739-A1 | BENZOTHIAZOLE HYBRIDS USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | Council Of Scientific & Industrial Research (IN) | 2013-12-11 | — | — | EP | disclosed |
| US-20130053415-A1 | COMBINATION METHODS FOR TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-02-28 | — | — | US | disclosed |
| EP-2544686-A2 | COMBINATION METHODS FOR TREATMENT OF DISEASE | Whitehead Institute For Biomedical Research (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2012104875-A1 | BENZOTHIAZOLE HYBRIDS USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-08-09 | — | — | WO | disclosed |
| EP-1069915-B1 | HYDROXYLATION ACTIVATED DRUG RELEASE | UNIV MONTFORT (GB) | 2003-06-25 | — | — | EP | disclosed |
| WO-2003048096-A1 | SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS | AVENTIS PHARMA S.A. (FR) | 2003-06-12 | — | — | WO | disclosed |
| US-6346550-B2 | TYROSINE KINASE INHIBITOR; ANTITUMOR AGENT | DE MONTFORT UNIVERSITY (GB) | 2002-02-12 | — | — | US | disclosed |
| US-20010021717-A1 | Hydroxylation activated prodrugs | DE MONTFORT UNIVERSITY | 2001-09-13 | — | — | US | disclosed |
| US-6214886-B1 | INHIBITING GROWTH OF TUMOR CELLS VIA STYRENE-DERIVED PRODRUGS WHICH ARE ACTIVATED BY ACTIVITY OF A HYDROXYLASE | DEMONTFORT UNIVERSITY, THE GATEWAY (GB) | 2001-04-10 | — | — | US | disclosed |
| EP-1069915-A2 | HYDROXYLATION ACTIVATED DRUG RELEASE | DE MONTFORT UNIVERSITY (GB) | 2001-01-24 | — | — | EP | disclosed |
| EP-1051383-A1 | HYDROXYLATION ACTIVATED PRODRUGS | DE MONTFORT UNIVERSITY (GB) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999040944-A2 | HYDROXYLATION ACTIVATED DRUG RELEASE | DE MONTFORT UNIVERSITY (GB) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999040056-A1 | HYDROXYLATION ACTIVATED PRODRUGS | DE MONTFORT UNIVERSITY (GB) | 1999-08-12 | — | — | WO | disclosed |
| JP-H08188546-A | CHALCONE DERIVATIVE | KYOWA HAKKO KOGYO CO LTD | 1996-07-23 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039190-A1 | BENZOTHIAZOLE HYBRIDS USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | TP53, MCL1, SDHA | TUBB1 105/4885TUBB4A 40/4885TUBB 112/4885 |
| US-20010021717-A1 | Hydroxylation activated prodrugs | CYP1B1, CYP1A1, CYP1A2 | TUBB1 1985/4885TUBB4A 2099/4885TUBB 2189/4885 |
| US-20130053415-A1 | COMBINATION METHODS FOR TREATMENT OF DISEASE | NFATC1, IRF3, BCOR | TUBB1 439/4885TUBB4A 969/4885TUBB 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.